Saturday 17 October 2026 Export NBIX’s income statement to Excel — free account

Neurocrine Biosciences, Inc.

NBIX Healthcare Drug Manufacturers Specialty & Generic

Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.

135.71 1.24 −0.91%

Follow NBIX

Alert me

Market cap: $13.9B
P/E: 19.2×
Fwd P/E: 30.5×
Dividend yield: —
F-score: 7/9
Altman Z: 7.80
Beneish M: −2.64
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 77.87

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	4	3	1	—	—	—	6	5	4	—	3	—

Insider Ownership 0.57%

Capital & Financial Ratios $m

Market Cap 13,920.00

Revenue 3,373.90

Net Income 705.50

Free Cash Flow 870.40

Net Debt (389.80)

Current Ratio 1.87

Debt/Equity 0.00

P/E ratio 19.25

Fwd P/E 30.50

P/S ratio 4.06

P/B ratio 3.71

Past 5Y EPS Growth 2.34%

This Y EPS Growth 51.09%

Next Y EPS Growth 37.70%

Next Y revenue growth 36.44%

Next 5Y EPS Growth 38.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 2.14%

10-year low 10-year high

P/S against its own 10 years 0.37%

10-year low 10-year high

P/B against its own 10 years 0.22%

10-year low 10-year high

EV/Sales against its own 10 years 1.58%

10-year low 10-year high

EV/FCF against its own 10 years 1.92%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,032	1,076	1,480	390
Receivables	439	479	687	887
Inventory	38	57	69	104
Other	98	64	116	39
	1,607	1,725	2,523	1,638

	2023	2024	2025	Q'26
Payables	449	462	674	808
ST’ Debt	—	—	—	—
Other	36	46	69	66
	655	508	743	875

Compound Annual Growth %

	10y	5y	3y
Sales	64.45%	22.29%	24.32%
Cash Flow	0.00%	27.92%	32.12%
Earnings	0.00%	3.28%	45.77%
Book Value	22.59%	23.63%	23.96%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	815	959	—	—	—
’25	573	688	795	806	2,861
’24	515	590	622	628	2,355
’23	420	453	499	515	1,887
’22	311	378	388	412	1,489
’21	237	289	296	312	1,134
’20	237	302	259	248	1,046

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	146	136	—	—	—
’25	65	102	228	388	783
’24	130	65	158	243	595
’23	(125)	180	212	124	390
’22	(40)	138	99	143	339
’21	87	103	62	4	257
’20	36	119	(20)	95	229

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	137	129	—	—	—
’25	54	90	214	391	749
’24	119	53	150	235	557
’23	(134)	173	204	118	362
’22	(48)	129	101	141	323
’21	83	99	56	(5)	233
’20	34	114	(21)	90	218

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	1.91	1.39	—	—	—
’25	0.08	1.06	2.04	1.48	4.67
’24	0.42	0.63	1.24	1.00	3.29
’23	(0.79)	0.95	0.82	1.44	2.47
’22	0.14	(0.18)	0.69	0.88	1.56
’21	0.33	0.43	0.23	(0.08)	0.92
’20	0.39	0.81	(0.62)	3.58	4.16

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	31.25	38.38	64.72	67.10	72.14	78.31	71.88	89.04	110.95	84.23	Analyst estimates 2026–2028 Powerpack
	High	55.94	78.05	126.98	119.65	136.26	120.27	129.29	133.64	157.98	160.18
People
People	Employees	196	400	585	700	845	900	1,200	1,400	1,800	2,000
	Revenue/emp, $m	0.08	0.40	0.77	1.13	1.24	1.26	1.24	1.35	1.31	1.43
Income, $m
Income, $m	Revenue	15	162	451	788	1,046	1,134	1,489	1,887	2,355	2,861
	Gross margin, %	100.00	99.22	98.91	99.06	99.03	98.74	98.44	97.90	98.56	98.18
	EBT	(141)	(143)	22	47	107	101	214	332	486	705
	EBT margin, %	(940.60)	(88.19)	4.83	5.90	10.20	8.95	14.37	17.60	20.63	24.66
	Net income	(141)	(143)	21	37	407	90	155	250	341	479
	Depreciation	5	16	23	28	30	36	19	3	1	17
Per share, $
Per share, $	Revenue	0.17	1.83	5.00	8.60	11.23	11.98	15.54	19.32	23.46	28.75
	Earnings	(1.63)	(1.62)	0.23	0.40	4.38	0.95	1.61	2.56	3.40	4.81
	Cash flow	(1.22)	(1.07)	1.12	1.60	2.45	2.71	3.54	3.99	5.93	7.87
	Capex	(0.05)	(0.08)	(0.27)	(0.16)	(0.12)	(0.25)	(0.17)	(0.29)	(0.38)	(0.34)
	Free cash flow	(1.27)	(1.15)	0.85	1.44	2.34	2.46	3.37	3.70	5.55	7.52
	Book value	3.63	4.22	5.33	6.95	12.10	14.52	17.83	22.85	25.79	32.69
	Shares, m	87	88	90	92	93	95	96	98	100	100
Valuation, ×
Valuation, ×	P/E	0.00	0.00	324.59	268.73	21.98	89.65	74.58	51.86	40.38	29.43
	P/S	92.53	39.55	14.28	12.49	8.53	7.11	7.73	6.82	5.82	4.93
	P/B	10.65	18.77	13.40	15.46	7.92	5.86	6.74	5.77	5.29	4.34
	EV/Sales	84.07	38.72	14.54	12.24	8.44	7.11	7.38	6.57	5.60	4.61
	EV/FCF	(27.62)	(67.54)	85.67	72.91	40.55	34.60	34.04	34.27	23.66	17.61
Cash, $m
Cash, $m	Operating cash flow	(106)	(94)	101	147	229	257	339	390	595	783
	Capex	(4)	(7)	(25)	(15)	(11)	(23)	(16)	(28)	(38)	(34)
	Free cash flow	(110)	(101)	77	132	218	233	323	362	557	749
Balance, $m
Balance, $m	Working capital	280	500	650	266	830	727	916	952	1,217	1,779
	Total debt	1	370	388	87	318	335	281	—	—	—
	Net debt	(307)	(146)	(262)	(583)	(483)	(376)	(989)	(1,032)	(1,076)	(1,480)
	Shareholders’ equity	315	372	481	637	1,126	1,374	1,708	2,232	2,590	3,253
Returns, %
Returns, %	ROA	(33.60)	(24.10)	2.33	3.22	26.79	4.71	6.96	8.89	9.79	11.46
	ROIC	(1,130.99)	(36.36)	10.53	84.62	15.84	6.42	21.66	13.06	23.56	21.83
	ROE	(38.17)	(41.50)	4.95	6.62	46.20	7.17	10.03	12.68	14.16	16.38

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UTHR United Therapeutics Corporation	$23.2B	17.6×	20.1×	−1.92% (below 0%: shrinking)	+13.99% (above 0%: growing)	+58.76% (above 0%: growing)	87.30%	42.23%	Compare
VTRS Viatris Inc.	$20.9B	— (loss-making)	61.1×	+4.88% (above 0%: growing)	n/m	+101.08% (above 0%: growing)	38.77%	0.17%	Compare
NBIX Neurocrine Biosciences, Inc.	$13.9B	19.2×	30.5×	+39.49% (above 0%: growing)	+31.19% (above 0%: growing)	+43.69% (above 0%: growing)	97.58%	15.80%
ELAN Elanco Animal Health Incorporated	$11.8B	— (loss-making)	278×	+10.23% (above 0%: growing)	+450.00% (above 0%: growing)	+35.56% (above 0%: growing)	58.33%	7.97%	Compare
RDY Dr. Reddy's Laboratories Ltd	$10.7B	32.9×	24.3×	−14.44% (below 0%: shrinking)	−70.00% (below 0%: shrinking)	−143.40% (below 0%: shrinking)	46.54%	4.81%	Compare
HIMS Hims & Hers Health, Inc.	$6.9B	— (loss-making)	— (loss-making)	+38.25% (above 0%: growing)	n/m	+5.09% (above 0%: growing)	63.83%	(12.90%)	Compare
ALKS Alkermes plc	$6.7B	102×	— (loss-making)	+26.97% (above 0%: growing)	−99.43% (below 0%: shrinking)	+1.13% (above 0%: growing)	80.22%	3.70%	Compare
LNTH Lantheus Holdings, Inc.	$6.5B	23.7×	25.3×	+2.68% (above 0%: growing)	0.00%	+13.55% (above 0%: growing)	62.30%	25.82%	Compare
KNSA Kiniksa Pharmaceuticals International, plc	$6.2B	73.4×	38.7×	+55.36% (above 0%: growing)	+37.50% (above 0%: growing)	+66.63% (above 0%: growing)	90.32%	11.16%	Compare
Median of peers	$8.8B	32.9×	32.0×	+7.56%	+7.00%	+24.56%	63.06%	6.39%

All 86 Drug Manufacturers Specialty & Generic stocks →

Neurocrine Biosciences, Inc. (NBIX) key facts

Strength: Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
Neurocrine Biosciences, Inc. (NBIX) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, NBIX traded at $135.71, a market capitalization of $13.9 billion.
Return on equity was 16.4% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 7.80 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.